"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...

"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of ...

“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS. In this video, Adam Lorentz, MD, FACS, ...

Fast track designation for 64Cu-SAR-bisPSMA enables accelerated development and review for prostate cancer imaging. Phase 1/2 COBRA trial showed 64Cu-SAR-bisPSMA's efficacy in detecting lesions missed ...

"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive ...

“They come out of the fellowship competent and competitive in the field to any urology position that they're interested in,” says Tania Solomon, PA-C, MSc. In this video, Tania Solomon, PA-C, MSc, ...

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context ...

Patient-centered pathology reports (PCPRs) significantly improve patient comprehension of prostate cancer diagnosis and risk levels compared to standard reports. In the study, 93% of PCPR recipients ...

UGN-101 showed a 68% three-year RFS rate in low-grade UTUC patients, with a median follow-up of 23.5 months. Maintenance therapy significantly improved RFS, but further studies are needed to confirm ...

"If you can do this surgery well, patients actually go back to living a normal life, and they're immensely, immensely happy," says Jaspreet S. Sandhu, MD. In this video, Jaspreet S. Sandhu, MD, ...

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse ...

The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.